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Abstract
Viruses are obligate intracellular parasites that alter the environment of infected cells in order to
replicate more efficiently. One way viruses achieve this is by modulating cell cycle progression. The
main regulators of progression out of G0, through G1, and into S phase are the members of the
retinoblastoma (Rb) family of tumor suppressors. Rb proteins repress the transcription of genes
controlled by the E2F transcription factors. Because the expression of E2F-responsive genes is
required for cell cycle progression into the S phase, Rb arrests the cell cycle in G0/G1. A number
of viral proteins directly target Rb family members for inactivation, presumably to create an
environment more hospitable for viral replication. Such viral proteins include the extensively
studied oncoproteins E7 (from human papillomavirus), E1A (from adenovirus), and the large T
(tumor) antigen (from simian virus 40). Elucidating how these three viral proteins target and
inactivate Rb has proven to be an invaluable approach to augment our understanding of both
normal cell cycle progression and carcinogenesis. In addition to these proteins, a number of other
virally-encoded inactivators of the Rb family have subsequently been identified including a surprising
number encoded by human herpesviruses. Here we review how the human herpesviruses
modulate Rb function during infection, introduce the individual viral proteins that directly or
indirectly target Rb, and speculate about what roles Rb modulation by these proteins may play in
viral replication, pathogenesis, and oncogenesis.
Background
The members of the retinoblastoma family of tumor sup-
pressors, Rb, p107 and p130, are transcriptional co-
repressors that regulate both differentiation and cell cycle
progression. Detailed reviews on genetic and molecular
analysis of the Rb pathway in normal and cancerous cells
are numerous [1-6] so here we will only briefly introduce
this pathway prior to describing how it is manipulated by
the human herpesviruses.
In the G0 and G1 phases of the cell cycle the active, hypo-
phosphorylated form of Rb binds to transcription factors
of the E2F family [7-9]. Through heterodimerization with
the DP proteins, E2Fs bind to promoters and control the
transcription of genes that are involved in many impor-
tant cellular functions including cell cycle progression
[2,10], DNA replication [11,12], the DNA damage
response [13], apoptosis [14-18], differentiation and
development [19-21], senescence [22], and angiogenesis
[23]. Rb, which itself is an E2F-responsive gene [24],
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binds to E2Fs at these promoters to actively repress tran-
scription by blocking the E2F activation domain, and by
recruiting histone-modifying enzymes such as histone
deacetylases (HDACs) [25-28] and chromatin remodeling
proteins such as the members of the hSWI/SNF complex
[29-31]. There are multiple E2F proteins, some considered
mainly as transcriptional repressors, and others with more
prominent roles as transcriptional activators.
Many cellular and viral proteins interact with the pocket
domain of Rb [32] that consists of A and B subdomains
and affords a large surface area to support strong and spe-
cific interactions. One common amino acid sequence
found in proteins that interact with the Rb pocket is the
LxCxE motif [25,26,33-35]. More than twenty cellular
proteins such as HDACs, and a number of viral proteins
interact with Rb in an LxCxE-dependent manner [35-37].
The Rb-binding LxCxE motif interacts with a site within
the Rb pocket termed the cleft region. The E2F proteins do
not contain LxCxE motifs and bind to a distinct site within
the Rb pocket domain, allowing Rb to interact with both
an E2F and HDAC simultaneously to repress transcription
of E2F-responsive promoters.
HDAC-Rb-E2F complexes are disrupted during the natu-
ral progression of cells out of G0, through G1, and into
the S phase. In a sequential and coordinated fashion, dif-
ferent cyclin proteins are expressed and they bind to and
activate a family of cyclin-dependent kinases (Cdks). Cer-
tain cyclin/Cdk complexes control cell cycle progression,
whereas others modulate the function of the RNA
Polymerase II transcriptional complex [38,39]. Small
molecule inhibitors of Cdk activity often inhibit multiple
members of both the "cell cycle" Cdks and the "transcrip-
tion" Cdks [40,41], so prescribing the effects of these
inhibitors solely to modulation of cell cycle processes
must be done judiciously. The Rb protein is one of the
main "cell cycle" Cdk substrates, containing 16 putative
Cdk phosphorylation sites. Hyperphosphorylation of Rb
by a series of cyclin/Cdk pairs causes the disruption of
HDAC-Rb-E2F complexes [2,5,6,10,30,42-45], allowing
for the activation of E2F-responsive genes and the subse-
quent progression of cells through G1 and into the S
phase. Phosphorylation at any one site is insufficient to
disassemble complexes between Rb and its binding pro-
teins, whereas the accumulation of multiple phosphoryla-
tions appears to be necessary for complex disruption
[43,44].
Cyclins D, E and A, in that order, are the targeting mod-
ules that direct the Cdks to phosphorylate different sub-
sets of Cdk consensus sites on Rb. The D-type cyclin
proteins have both an LxCxE motif and a region termed
the hydrophobic patch that contribute to both substrate
and substrate site specificity [46-48]. Cyclins E and A con-
tain a hydrophobic patch but lack LxCxE motifs. As men-
tioned above, the LxCxE motif binds within the cleft
domain of Rb [34,37]. The hydrophobic patch binds to
RxL motifs located within the C-terminus of Rb [49].
Because the phosphorylation of Rb by cyclin/Cdks repre-
sents a critical juncture in the control of cell cycle progres-
sion, this is a tightly regulated process. Multiple levels of
regulation exist that include temporal cyclin expression,
activating and inhibitory phosphorylation of Cdks, and
the direct binding and inhibition of cyclin/Cdk complexes
by two classes of small proteins termed the cyclin-depend-
ent kinase inhibitors (Ckis) [50,51]. Additionally, Rb
must return to a hypophosphorylated form during mitosis
so that the cell cycle can be reset. This is achieved by the
action of protein phosphatase I (PPI) [52-54]. Although
there is little evidence that Rb is regulated by degradation
during normal cell cycle progression, the over expression
of the cellular protein gankyrin can result in Rb degrada-
tion [55] through a process that requires an intact LxCxE
motif of gankyrin [56].
The pathway controlled by Rb is thought to be inactivated
in most if not all human cancers [2,57]. Common mech-
anisms of pathway disruption include the over-expression
and stabilization of cyclin D [1,58,59], inactivation of the
Cki p16 [60,61], or the expression of a viral oncoprotein
[62]. Certain cancers also have activating Cdk mutations
[63,64], Rb loss or mutation [65], or gankyrin over-
expression [55]. The other members of the Rb family,
p107 and p130, also regulate E2F-mediated gene expres-
sion and are targets of the Cdks. But whereas Rb is present
throughout the cell cycle, p107 and p130 each have a
more limited window of expression. The p130 protein is
found predominantly in G0 cells [66,67], is rapidly phos-
phorylated upon entry into G1 [66,68], and swiftly
degraded following phosphorylation [69]. The p107 pro-
tein is expressed as cells begin to enter the S phase [67,70].
While Rb is often mutated in human cancers and thus is
considered a true tumor suppressor protein, p130 is infre-
quently mutated [71-76], and no p107 mutations in
human cancers have been identified.
DNA tumor viruses inactivate Rb
Cells must synthesize large amounts of DNA to replicate
their genomes during the cell division cycle. Both
enzymes that synthesize or metabolize deoxynucleotides,
as well as enzymes that directly or indirectly facilitate
deoxynucleotide polymerization are required for DNA
synthesis. The coordinated production of these required
enzymes is achieved by placing them under the control of
the E2F transcription factors that in turn are regulated by
Rb. Because viruses with DNA genomes must also synthe-
size significant quantities of this nucleic acid during their
productive, lytic replication phases, many have evolvedCell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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ways to modulate the Rb-E2F pathway. Viral inactivation
of Rb has been most extensively studied through examin-
ing the relevant transforming oncoproteins of the DNA
tumor viruses, namely the Adenovirus E1A protein, the
Papillomavirus E7 protein, and the Simian Virus 40
(SV40) large tumor (T) antigen. Many excellent reviews of
these proteins have been published [77-79]. While the
focus of this review is herpesvirus proteins that modulate
the Rb pathway, a brief description of the DNA tumor
virus proteins that also accomplish this task is presented
to provide a platform for comparison and contrast.
Adenovirus E1A contains an LxCxE motif (the conserved
region 2 (CR2) domain) that interacts in the Rb cleft [80-
82], and a second motif (CR1) that competes with E2F for
binding to Rb [80-82]. In this manner, E1A disrupts com-
plexes between the E2Fs and all three Rb family members.
E1A expression stimulates cell cycle progression and
cooperates with other viral or cellular oncogenes to trans-
form cells. For many years no association between adeno-
viral infection and human cancers could be identified, but
a recent study has observed a link between fetal adenovi-
ral infections and childhood acute lymphoblastic leuke-
mia [83].
The human papillomavirus encoded E7 also contains an
LxCxE motif, binds to all three Rb proteins, and induces
their degradation through the ubiquitin-proteasome
pathway [84-88]. In addition to the LxCxE domain, N-ter-
minal sequences of unknown function are required for
E7-induced Rb degradation [89]. The exact mechanism of
degradation has not yet been determined. It was initially
speculated that E7-mediated degradation occurred
through a direct interaction with the proteasome because
E7 was found to bind to the S4 subunit of the 26S protea-
some [90]. However, E7 mutants that fail to bind S4 still
induce Rb degradation [87]. Recently, E7 has been found
to associate with an active cullin 2-based cellular ubiqui-
tin ligase complex [91], thus it is possible that E7 redirects
this cellular complex to ubiquitinate Rb. While infection
with some papillomavirus genotypes (termed high risk)
can lead to cervical cancer, infection with other genotypes
(low risk) does not [87]. The E7 proteins from high risk
papillomavirus subtypes efficiently bind and degrade Rb,
and cooperate with other viral or cellular oncoproteins to
transform cells [87]. E7 proteins from low risk HPV fail to
transform cells but still bind and degrade Rb, although
with lower efficiency than the high risk HPV E7 proteins
[92].
SV40 T Antigen contains an LxCxE motif, binds to all three
Rb proteins [93-95], and disrupts Rb-E2F complexes [96-
98]. An additional T antigen domain with sequence
homology to the cellular chaperone DNA J is also required
for T antigen inactivation of all three Rb proteins
[99,100], and for dephosphorylation of p107 and p130
[98,100,101]. The role of T antigen-mediated dephospho-
rylation of p107 and p130 is not understood. SV40 has
never been definitively associated with human tumors,
although studies continue to examine a potential role for
SV40 infection via contaminated polio vaccines in mes-
otheliomas [99,102,103].
These three viral proteins represent two distinct mecha-
nisms of Rb inactivation: steric disruption of Rb-E2F com-
plexes and Rb degradation. Herpesviruses encode proteins
that use these, as well as other novel (direct and indirect)
mechanisms to inhibit Rb family member function (Fig-
ure 1). The study of E1A, E7, and T Antigen has proven to
be invaluable for the understanding of both the replica-
tion and pathogenesis of the viruses that encode them, as
well as to the normal regulation of the Rb-E2F pathway.
The study of herpesvirus-encoded proteins that modulate
Rb through novel mechanisms should therefore also lead
to a better understanding of both herpesviral replication
and pathogenesis, as well as Rb family protein functional
regulation during cell cycle progression and oncogenesis.
Human herpesviruses
Prior to the genomics era, herpesviruses [104] were easily
distinguishable because of their characteristic morphol-
ogy [105,106]. Genome-containing icosahedral capsids
are surrounded first by an amorphous layer of proteins
termed the tegument, and subsequently by a lipid enve-
lope. Viral glycoproteins in the virion envelope mediate
fusion with, and entry into cells. Both the capsid and teg-
ument are released into the cytoplasm. Tegument proteins
modulate host cell processes even before the production
of newly synthesized viral proteins from the infecting
genomes, and help deliver the capsid along microtubules
to the nuclear pore complex, where the genome is injected
into the nucleus [107]. The linear, double-stranded DNA
genome circularizes within the nucleus. Herpesvirus
genomes [108,109] range in size from 120-kb and
approximately 70 genes for Varicella Zoster Virus (VZV) to
235-kb and approximately 170 genes for human cytome-
galovirus (HCMV). To start a productive, lytic replication
cycle [110,111], a temporal and sequential cascade of
immediate early (IE), early (E) and late (L) gene expres-
sion is initiated [104]. Viral DNA replication produces
long concatamers that are packaged as unit length linear
genomes into capsids within the nucleus. Newly formed
capsids traverse the double nuclear envelope through an
envelopment, de-envelopment pathway, acquire their teg-
ument proteins and envelopes at cytoplasmic assembly
sites derived form golgi membranes, and then exit the cell
by the exocytosis of virion containing vesicles [104]. Dur-
ing latency, viral genomes are maintained as episomes
(they generally do not integrate into host chromosomes),
significantly fewer viral genes are expressed (the numberCell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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Mechanisms used by different classes of human herpesviruses to modulate the Rb-E2F pathway Figure 1
Mechanisms used by different classes of human herpesviruses to modulate the Rb-E2F pathway. See text for 
details. α. HSV-1 prevents Rb phosphorylation and keeps cellular Cdks inactive, likely through the downregulation of cyclin 
proteins and the mislocalization of Cdks. VZV infected cells display Cdk activity even though p21 and p27 are induced. How-
ever, Rb remains unphosphorylated through an uncharacterized mechanism.β. HMCV infected cells show a lack of hypophos-
phorylated Rb and high levels of hyperphosphorylated Rb, due to both pp71-mediated degradation and UL97-mediated 
phosphorylation. IE2 can also directly activate E2F-responsive genes.γ. EBV has multiple proteins (Z, R, LMP-1, EBNA-2,-3C,-5) 
that could lead to the phosphorylation of Rb by cellular Cdks, and/or may directly phosphorylate Rb thropugh the function of 
the viral kinase, BGLF-4. KSHV can activate the Rb pathway by LANA-mediated disruption of Rb-E2F complexes, or by direct 
phosphorylation of Rb through the action of the v-cyclin and/or the ORF36 proteins.Cell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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varies between the different viruses), and no infectious
virions are produced. Latent infections can be reactivated
to allow for the new production of infectious virions dec-
ades after the primary infection.
During lytic replication and in reactivating latent infec-
tions, herpesviruses must synthesize large quantities of
viral DNA. The analysis of DNA content in herpesvirus-
infected cells by flow cytometry indicates that cellular
genome equivalents of viral DNA are produced in these
cells. Therefore, herpesviruses must either rely on their
own viral machinery for the enzymes required for nucle-
otide biosynthesis, metabolism, and polymerization (Fig.
2), or induce the accumulation of the cellular enzymes
responsible for those same activities (Fig. 3). As many of
those cellular enzymes are encoded by E2F-responsive
genes, and as E2F-mediated gene expression is controlled
in large part by the Rb proteins, this family of tumor sup-
pressors is likely to be a critical target for the subset of her-
pesviruses that rely on cellular nucleotide biosynthetic
enzymes and other DNA replication-related enzymatic
functions for their replication.
The eight herpesviruses that infect humans are classified
into three families, the alpha-, beta-, and gammaherpesvi-
ruses (Fig. 4). Six of the eight human herpesviruses infect
the vast majority of adults (the exceptions are HSV-2 and
KSHV; see below for details). For each of these viruses, we
will briefly describe the clinical manifestations of infec-
tion, discuss in detail the fates and functions of the Rb
proteins in infected cells, and end with what we consider
to be timely and relevant questions for future exploration.
Alphaherpesviruses
The human alphaherpesviruses [112,113] include Herpes
Simplex Virus Type 1 (HSV-1, HHV-1 (Human Herpesvi-
rus 1)), HSV-2 (HHV-2), and Varicella Zoster Virus (VZV,
HHV-3). Both primary and reactivated infections with
HSV-1 typically cause oral lesions (cold sores), while HSV-
2 infections generally cause genital lesions although each
of these viruses can infect either location. Primary infec-
tion with VZV causes varicella (chicken pox) and reactiva-
tion of latent infections causes zoster (shingles). HSV-1
and VZV are very common infections, but HSV-2 infects
only about 8% of the population [114]. Alphaherpesvi-
ruses carry out productive, lytic replication in epithelial
cells, and establish latent infections in sensory neurons.
Neuroinvasiveness and their relatively rapid lytic replica-
tion cycle are defining characteristics of the alphaherpes-
viruses.
Herpes simplex virus type 1 and 2
Cells infected with HSV-1 accumulate in the G1 phase of
the cell cycle [115-117]. Serum-arrested (G0) cells do not
enter the S phase after infection, and G0 cells simultane-
ously infected and stimulated with serum also fail to enter
the S phase [115-118]. In these HSV-1 infected, G1
arrested cells, the steady-state levels of Rb do not detecta-
bly change and the protein is found in a hypophosphor-
ylated state bound to E2F proteins [116,118].
Inhibition of Rb phosphorylation in HSV-1 infected cells
The viral ICP27 protein (the 27th infected cell protein
observed) is required to prevent the phosphorylation of
Rb in HSV-1 infected cells [119]. ICP27 is a multifunc-
tional immediate-early protein that modulates gene
Genes for DNA replication machinery and nucleotide biosynthesis encoded by the human herpesviruses Figure 2
Genes for DNA replication machinery and nucleotide biosynthesis encoded by the human herpesviruses. Listed 
are the virally encoded genes involved or implicated in viral DNA replication (top), nucleotide biosynthesis (middle) and activa-
tion (by phosphorylation) of the nucleoside analogs (bottom) employed as anti-herpesviral drugs for the alpha- (yellow), beta- 
(blue) and gamma- (green) herpesviruses. Note the striking lack of nucleotide biosynthetic enzymes encoded by the betaher-
pesviruses.
HSV-I HSV-II VZV HCMV HHV-6 HHV-7 EBV KSHV
DNA replication machinery
DNA polymerase UL30 UL30 ORF28 UL54 U38 U38 BALF5 ORF9
DNA polymerase processivity subunit UL42 UL42 ORF16 UL44 U27 U27 BMRF1 ORF59
origin-binding protein, helicase UL9 UL9 ORF51 UL84 U73 U73 Zta K8/K-bZIP
helicase-primase ATPase subunit UL5 UL5 ORF55 UL105 U77 U77 BBLF4 ORF44
helicase-primase subunit C UL8 UL8 ORF52 UL102 U74 U74 BBLF2/BBLF3 ORF40/41
helicase-primase RNA pol subunit B, primase UL52 UL52 ORF6 UL70 U43 U43 BSLF1 ORF56
single strand DNA binding protein UL29 UL29 ORF29 UL57 U41 U41 BALF2 ORF6
origin-binding protein / priming ------- ORF50/Rta
Nucleotide biosynthesis
thymidine/nucleoside kinase UL23 UL23 ORF36 - - - BXLF1 ORF21
ribonucleotide reductase large subunit UL39 UL39 ORF19 UL45** U28** U28** BORF2 ORF61
ribonucleotide reductase; small subunit UL40 UL40 ORF18 - - - BaRF1 ORF60
deoxyuridine triphosphate nucleotidohydrolase UL50 UL50 ORF8 UL72** U45** U45** BLLF3 ORF54
uracil-DNA glycosidase UL2 UL2 ORF59 UL114 U81 U81 BKRF3 ORF46
dihydrofolate reducatse ------- ORF2
thymidylate synthetase - - ORF13 ---- ORF70
Drug activation
nucleoside analog kinase UL23 UL23 ORF36, ORF47 UL97 U69 U69? BGLF4, BXLF1 ORF21, ORF36
** catalytically inactiveCell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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expression at multiple levels including transcription,
mRNA processing, and translation [120]. Along with the
tegument-incorporated virion host shut off (VHS) protein
(UL41, the 41st gene in the unique long region of the
genome) that degrades mRNAs [121], ICP27 plays a role
in the inhibition of host protein synthesis by inhibiting
mRNA splicing [122-124] (this has little effect on viral
gene expression because most herpesvirus genes are not
spliced). Host shut off likely contributes to, but is not suf-
ficient for the ability of ICP27 to inhibit Rb phosphoryla-
tion [119]. The ICP0 protein has been shown to arrest cell
cycle progression [125,126] although the role it plays in
Rb hypophosphorylation upon HSV-1 infection has not
been examined. Likewise, the combined roles that ICP0
and ICP27 may play in the G1 arrest instituted by HSV-1
have not been resolved.
Infection with an ICP27-null virus results in Rb phospho-
rylation [119] although the kinase(s) responsible for this
phosphorylation has not been identified. Likely candi-
dates, however, would include the cellular kinase com-
plexes composed of cyclin D/Cdk4,6 and cyclin E/Cdk2,
as these complexes are known to phosphorylate Rb in
uninfected cells. These kinases are inactive in wild-type
HSV-1 infected cells for multiple reasons, such as the fail-
ure of cyclins to accumulate [115,117], the sequestering of
Cdks in the cytoplasm [117], and the inhibition of preex-
isting cyclin/Cdk complexes by an unresolved mechanism
that may be independent of the Cki proteins [117]. Fur-
ther experiments performed in cells infected with ICP27
or ICP0-null HSV-1 could help define how Rb is regulated
upon HSV-1 infection. It would be particularly interesting
to determine if small molecule Cdk inhibitors such as ros-
covitine or flavopiridol have any effect on Rb phosphor-
ylation in cells infected with these mutant viruses.
Curiously, one report indicated that Rb phosphorylation
is induced by HSV-2 infection even though progression of
infected cells into the S phase was inhibited [127], a situ-
ation analogous to HCMV infection (see below). Cyclin
A/Cdk1 was implicated in the phosphorylation of Rb in
HSV-2 infected cells [127]. A subsequent report was una-
ble to confirm this, but found that both HSV-1 and HSV-
2 did not induce Rb phosphorylation after infection of
quiescent cells, and caused Rb dephosphorylation after
infection of cycling cells [115]. A novel under-phosphor-
ylated form of Rb in HSV infected cells (termed b') has
been observed [115,117] although it is unclear whether
this represents a novel site of phosphorylation or just an
intermediately phosphorylated form. It is unlikely, how-
ever, that Rb-b' explains the different conclusions of the
independent HSV-2 studies [115,127]. Thus, more work is
needed to determine if Rb is regulated differently after
infection with these two similar viruses and, if so, how
Modulation of the steady-state levels of mRNAs for selected nucleotide biosynthetic enzymes by the different classes of human  herpesviruses Figure 3
Modulation of the steady-state levels of mRNAs for selected nucleotide biosynthetic enzymes by the different 
classes of human herpesviruses. Microarray data for virus-infected cells was mined to illustrate the extent to which cellular 
nucleotide biosynthetic enzymes were activated upon infection with the indicated viruses. See text for a detailed discussion. 
HSV-1 infection of mouse embryonic fibroblasts at 4, 8, and 12 hours post infection (hpi) [317], left lane. HSV-1 infection of rat 
superior cervical ganglia neurons at 6, 12, and 24 hpi (Szpara and Enquist, personal communication), right lane. HCMV infection 
of human foreskin fibroblasts at 20, 24, and 48 hpi [316]. KSHV infection and reactivation of endothelial cells at 24, 37, and 48 
hpi [315]. Red, up-regulated 2-fold or more in at least two out of three time points. Green, down-regulated 2-fold or more in 
at least two out of three time points. Black, any changes were less than 2-fold. Grey, not analyzed/not found. In cases where 
more than one probe set was present, fulfillment of above criteria by any one probe set was sufficient.
Gene Gene symbol        HSV-I HCMV KSHV
thymidine kinase TK1
ribonucleotide reductase RRM2
dUTPase DUT
uracil DNA glycosidase UNG
dihydrofolate reductase DHFR
thymidylate synthetase TYMS
adenylate kinase AK1
nucleoside diphosphate kinase NME7
PRPP amidotransferase PPAT
CTP synthase CTPS
FGAM synthase PFASCell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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that differential regulation affects viral replication, tro-
pism, or pathogenesis.
The preponderance of evidence supports a model in
which Rb is held in a hypophosphorylated (i.e. active)
state in HSV infected cells, possibly because G1 cyclin/
Cdk activity is low or absent. Interestingly, fibroblasts
derived from mouse Rb -/- embryos (Rb-null MEFs) show
no defects in supporting HSV-1 replication [128]. This
indicates either that active Rb is not required for HSV-1
infection, or that other pocket proteins (p107 or p130)
can compensate for Rb loss in these cells.
A critical role for p130 during HSV-1 infection
In quiescent (G0) cells, p107 is absent but upon serum
stimulation its expression is induced as cells enter the S
phase. HSV-1 infection coincident with serum stimula-
tion inhibits the accumulation of the p107 protein [117].
Expression of nucleotide biosynthetic enzymes during the lytic and latent phases of different classes of human herpesviruses Figure 4
Expression of nucleotide biosynthetic enzymes during the lytic and latent phases of different classes of human 
herpesviruses. See text for details. α. During lytic infection HSV-1 does not induce the expression of cellular NBEs (nucle-
otide biosynthetic enzymes), and thus appears to rely on viral NBEs. It is unclear if the shutoff of host protein synthesis con-
tributes to the absence of host NBE expression. During latency, viral genomes are not replicated and thus no NBEs appear to 
be required. Reactivation is assumed to be similar to lytic infection with a reliance on viral NBEs. β. During lytic infection 
HMCV robustly activates the expression of cellular NBEs, likely because it does not encode a full complement of viral NBEs. 
Reliance on NBEs during latency is not known because it is unclear if the viral genome replicates. However if viral genomic rep-
lication occurs, it is likely that cellular NBEs provide the needed nucleotides. Reactivation is assumed to be similar to lytic infec-
tion with a reliance on cellular NBEs. γ. During lytic infection EBV inactivates Rb and expresses its own NBEs, so both cellular 
and viral NBEs might be utilized. Note the shutoff of host protein synthesis during KSHV infection would appear to imply that 
viral NBEs play a more prominant role in KSHV lytic infection. During latency, viral proteins inactivate Rb and viral NBEs aren't 
expressed, implying a reliance on viral NBEs. Reactivation is assumed to be similar to lytic infection with a reliance on viral 
NBEs (for KSHV) or both viral and cellular NBEs (for EBV).Cell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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In asynchronous cells infected with HSV-1, p107-E2F
complexes were found to accumulate [118,129], a finding
consistent with dephosphorylation such as that seen with
Rb and p130 [117]. Similar to Rb, p107 function doesn't
appear to be vital to HSV-1 lytic replication as p107-null
MEFs support efficient viral replication [128].
HSV-1 infection inhibits the phosphorylation and subse-
quent degradation of the p130 protein that is observed as
G0 cells enter the G1 phase, and causes a re-accumulation
of hypophosphorylated p130 within infected G1 cells
[117]. Contrary to what was observed with Rb and p107,
p130 appears to be critical for lytic HSV-1 replication
[128]. In p130-null MEFs, HSV-1 shows a 10- to 100-fold
growth defect. A delay in IE gene expression was observed
in these cells, as well as subsequent defects in viral DNA
replication and late gene expression. The IE protein ICP0
was almost undetectable in these cells [128]. Because
ICP0 is a critical regulator of HSV-1 lytic replication
[130,131], it would be interesting to determine if ectopic
expression of ICP0 corrected the HSV-1 replication defects
observed in p130-null MEFs. HSV-1 infection failed to
downregulate Cdk2 activity in p130-null MEFs [128].
When these cells were synchronized in early G1 (where
Cdk2 activity is low), viral replication was partially res-
cued [117]. This is interesting because in addition to its
ability to regulate E2F-mediated gene expression, p130
(and p107, but not Rb) can also function as a Cdk inhib-
itor [132-135]. Thus, the ability of the virus to downregu-
late G1 cyclin/Cdk activity through the action of the p130
protein (and not p130's effects on E2F) may be critical for
efficient HSV-1 replication. However, one must remember
that compensation between the Rb family members may
occur in null MEFs [136]. So firm conclusions about the
necessity of the individual pocket proteins for HSV-1 rep-
lication await independent confirmation.
A notable corollary to these results is that while the Rb
proteins remain unphosphorylated in HSV-infected cells,
the activity of kinases responsible for their phosphoryla-
tion, the Cdks, appears to be critical for HSV-1 replication
[137]. Cdk activity is required for the efficient expression
of viral genes [138]. Although the mechanism is not com-
pletely understood, transcriptional Cdks may contribute
to HSV infection by regulating cellular RNA Polymerase II
function [139] and/or enhancing the ability of the viral
ICP0 protein to activate transcription [140]. Interestingly,
the viral UL42 protein may serve to target the Cdks to their
substrates in some of these putative phosphorylation
events [141], either instead of, or in addition to, cellular
cyclins.
Varicella Zoster Virus
Cells infected with VZV do not progress into the S phase,
but appear to arrest at the G1/S border [142]. Rb and p107
are not phosphorylated in VZV infected cells [142], simi-
lar to the results described above for HSV-1. The status of
p130 in VZV infected cells has not been examined. How-
ever, unlike HSV-1, VZV infection induces the expression
of cyclins D3, A, and B1 (but not cyclin E), and elevated
Cdk2 and Cdk4 activity is observed [142,143]. Interest-
ingly, this Cdk activity was observed in the presence of the
Cki proteins p21 and p27. It is still unclear how these
kinases remain active but do not phosphorylate Rb, a nor-
mal activity of these cyclin/Cdk complexes.
Small molecule Cdk inhibitors also inhibit VZV infection
[144,145]. The broad spectrum Cdk inhibitor roscovitine
reduces viral gene expression, viral DNA replication, and
infectious virion formation [144], and a selective inhibi-
tor of Cdk1 prevents the phosphorylation of the IE62 pro-
tein (immediate early protein of 62 kDa), a viral
transcription factor [145]. Thus in a manner similar to
HSV-1, Cdks seem to regulate viral gene expression, but
not Rb protein phosphorylation, in VZV infected cells.
Alphaherpesvirus summary
While Cdk activity clearly contributes to alphaherpesvirus
infections, the Rb family proteins do not appear to be crit-
ical substrates of these kinases in cells infected with HSV-
1, HSV-2, or VZV. These observations lead to two subse-
quent questions: why doesn't active Rb inhibit the replica-
tion of these DNA viruses, and what are the significant
substrates of the active Cdks in alphaherpesvirus infected
cells?
A potential answer to the first question is revealed upon a
genomic comparison of the different human herpesvi-
ruses. While the cadre of DNA synthesis functions
encoded by the three different classes of herpesviruses is
similar, the alpha- and gammaherpesviruses encode con-
siderably more nucleotide biosynthetic enzymes than the
betaherpesviruses (Fig. 2). Thus, alphaherpesviruses (and
perhaps gammaherpesviruses) may be less dependent on
cellular E2F-responsive genes for viral DNA replication
than the betaherpesviruses (see below) and therefore may
not need to target Rb family members for inactivation
(Fig. 1).
Candidates for important Cdk substrates in alphaherpes-
virus infected cells include viral proteins and cellular RNA
polymerase II. Determining whether the ''cell cycle'' Cdks
(Cdk1, 2, 4, 6), the ''transcription'' Cdks (Cdk7, 9), or
both are relevant targets for the broad spectrum Cdk
inhibitors that decrease alphaherpesvirus replication may
help define the critical targets of the kinases in infected
cells. Also, determining how the Cdks recognize their tar-
gets could also be informative. Are cyclin/Cdk complexes
relocalized during infection? Do viral proteins supplant
cellular cyclins and re-direct Cdks to different substrates?Cell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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Answers to these questions may help to resolve how Rb
family members remain in their hypophosphorylated
forms during alphaherpesvirus lytic infections even
though some Cdks are active. Finally, the roles of Rb pro-
teins and Cdks during latency of these viruses should be
examined.
Betaherpesviruses
The human betaherpesviruses [111,146-150] include
Human Cytomegalovirus (HCMV, HHV-5), Human Her-
pesvirus 6A and 6B (HHV-6) and Human Herpesvirus 7
(HHV-7). These viruses are extremely common, with
more than 90% of the population infected [147,149,151-
153]. HCMV infections are mostly asymptomatic in
healthy adults, but can cause severe disseminated disease
in immunocompromised and immunosuppressed people
[151]. HCMV is the leading infectious cause of birth
defects, contributes to graft loss in transplant patients, is
associated with atherosclerosis and restenosis, and
becomes the major target of host cell-mediated immunity
in older people, leading to immunosenescence [154]. A
causative role in human malignancies has not been dem-
onstrated, but HCMV is being evaluated as a cofactor for
certain cancers, most notably glioblastoma. HHV-6 and
HHV-7 are causative agents of exanthem subitum (''sud-
den rash''), a mostly benign disease in young children
characterized by a fever and subsequent red rash (roseola)
[150]. Collectively HHV-6 and HHV-7 are termed the
Roseolaviruses. Like HCMV, reactivation of latent HHV-6
and HHV-7 infections in immunocompromised or immu-
nosuppressed patients can be problematic. Betaherpesvi-
ruses are lymphotropic, but the true latent reservoirs of
these viruses remain undefined. Lytic replication cycles
are slow and can occur in multiple cell types in vivo, but
are generally restricted to non-transformed human cells in
culture. Persistent replication in salivary glands may be
important for the natural transmission of these viruses to
new hosts.
Human cytomegalovirus
Infection of quiescent fibroblasts with HCMV results in
their reentry into the cell cycle, progression through the
G1 phase, and an eventual arrest at the G1/S border [155-
161]. Infection of cycling cells also induces a G1/S arrest
[160-162]. In G0 arrested cells, HCMV infection causes
elevated levels of Rb which accumulate solely in the
hyperphosphorylated form [156]. An examination of the
very early stages of HCMV infection of quiescent fibrob-
lasts indicated that hypophosphorylated Rb is first
degraded, and then phosphorylated [163]. Both activities
appear to be required for the absence of hypophosphor-
ylated Rb, and the accumulation of hyperphosphorylated
Rb during HCMV infection. Multiple HCMV proteins
have been presented as candidate regulators of the Rb
family proteins by degradation, phosphorylation or sim-
ple binding and inactivation. Furthermore, it is possible
that HCMV can directly activate E2F-mediated gene
expression independently of Rb. The individual viral pro-
teins that modulate Rb, and the roles that they play in
viral infection are discussed below.
Rb degradation in HCMV infected cells
The HCMV pp71 protein (a phospho-protein of 71 kDa)
is a prominent component of the viral tegument
[107,164] that binds to Rb and induces its degradation in
a proteasome-dependent, ubiquitin-independent manner
[165,166]. pp71 also binds and degrades p107 and p130
[166]. An LxCxD sequence in pp71 is required for Rb fam-
ily degradation and for the ability of ectopically expressed
pp71 to drive quiescent cells into the S phase of the cell
cycle, as a mutant pp71 with an LxGxD motif (called
C219G) failed to function in these assays [166]. pp71 can
also accelerate progression through the G1 phase of the
cell cycle by an unknown mechanism that is likely Rb-
independent, because the LxCxD motif is not required for
this activity [167]. Interestingly, pp71-mediated cell cycle
stimulation does not induce apoptosis and pp71 is unable
to cooperate with cellular or viral oncogenes to transform
primary rodent cells in vitro [166,168], unusual properties
for an Rb inactivating protein.
The early work on pp71 degradation of Rb was performed
outside of the context of an HCMV infection, and in cell
types non-permissive for HCMV infection. More recent
experiments have addressed the role for this function of
pp71 in HCMV infected, fully permissive fibroblasts in
vitro. A virus expressing only the C219G mutant from of
pp71 replicates as well as wild-type HCMV [169], indicat-
ing that at least in fibroblasts in vitro, Rb degradation by
pp71 is not required for lytic replication, perhaps due to
the multiple, redundant mechanisms HCMV uses to mod-
ulate the Rb-E2F pathway (see below). However, infection
with this C219G mutant virus was used to demonstrate
that pp71 is required for the degradation of hypophos-
phorylated Rb at very early times after HCMV infection
[163]. pp71 is introduced into cells immediately upon
infection and mediates the transient drop in the steady
state levels of Rb that can be seen as soon as 2 hours after
infection [163].
Although Rb degradation by tegument-delivered pp71
may not be required for lytic replication, degradation of
another pp71 substrate, the Daxx protein, greatly
enhances lytic replication [169-173]. Daxx is a transcrip-
tional co-repressor that silences the HCMV major imme-
diate early promoter (MIEP) [172,174,175]. The MIEP
controls the expression of the viral IE proteins that, when
expressed, commit the virus to the lytic replication cycle.
By degrading Daxx, pp71 relieves this repression, facilitat-
ing IE gene expression and lytic replication. Because IECell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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proteins, and an early protein (UL97) whose expression is
activated by them, also regulate Rb (see below), pp71
appears to have both direct and indirect effects on the Rb-
E2F pathway. Daxx degradation by pp71 is especially
important during low multiplicity infections [169,170],
and maintaining Daxx-mediated repression of the MIEP
by preventing pp71 from degrading Daxx may contribute
to the IE gene silencing that is observed when latent infec-
tions are established [176].
Interestingly, the substrates of pp71 (both Rb and Daxx)
although initially degraded, re-accumulate at later times
after infection [163,164,170,177]. It is presently unclear
whether this is a result of an inhibition of pp71-mediated
degradation, enhanced production of these pp71 targets,
or both. Also unclear is the significance (and mechanism)
of the uncommon ubiquitin-independent mode of pro-
teasomal degradation mediated by pp71 [165,177].
Because pp71 can induce the degradation of its substrates
when expressed alone in cells [165,170,177], no other
viral proteins are required. However it is not known if cel-
lular proteins (other than the proteasome) are required
for pp71-mediated protein degradation. The importance
of pp71-induced protein degradation to HCMV lytic
infection and the uncommon method of that degradation
make this an attractive target for the development of an
inhibitory drug that may have potent antiviral activity but
limited toxicity to uninfected cells.
Rb phosphorylation in HCMV infected cells
The Rb protein becomes hyper-phosphorylated as soon as
4 hours after HCMV infection of quiescent (G0) cells
[156]. HCMV infection activates cyclin E- and cyclin B-
dependent kinase activity [156,159] (but not cyclin D- or
cyclin A-dependent kinase activity), and cyclin E/Cdk2
complexes are known to phosphorylate Rb. Thus it was
surprising to find that small molecule inhibitors of the
Cdks used at levels that completely inhibited serum
induced Rb phosphorylation had no effect on Rb phos-
phorylation in HCMV infected cells [163]. Studies with
additional inhibitors demonstrated that the activity of the
HCMV UL97 protein kinase was absolutely required for
Rb phosphorylation in HCMV infected cells [163]. UL97
directly phosphorylates Rb in vitro, and specifically targets
multiple residues that, when phosphorylated, disrupt Rb-
E2F and Rb/HDAC complexes, rendering Rb inactive
[163]. Ectopic expression of UL97 drives quiescent cells
into the S phase of the cell cycle [163], and recombinant
HCMVs that express either no [178] or a catalytically inac-
tive form of UL97 [163,179] fail to induce Rb phosphor-
ylation [163,180]. Thus the HCMV protein kinase UL97 is
necessary and sufficient for the phosphorylation and inac-
tivation of the Rb protein.
UL97 is a serine-threonine kinase [179] that augments,
but is not absolutely required for HCMV lytic replication
in fibroblasts in vitro [178]. UL97 null viruses have a sub-
stantial (100-fold) [178] growth defect that is partially
(10-fold) rescued by propagation on dividing cells [178].
Deletion of the UL97 gene or inhibition of UL97 kinase
activity results in a 5- to 20-fold decrease in viral DNA rep-
lication [181]. One might predict that this defect may be
due to lower levels of certain E2F-responsive genes
involved in nucleotide biosynthesis in these cells, and
experiments to address this hypothesis are currently
underway in our laboratory. Virion assembly and egress
are also adversely affected by the absence of UL97 kinase
activity [181], perhaps resulting from defects either in teg-
ument protein phosphorylation/localization [182,183],
or nuclear lamina breakdown [184]. UL97 is also a key
protagonist for the small arsenal of drugs available to treat
HCMV infections. UL97 is required to phosphorylate and
thus activate the ganciclovir family of antiherpesvirus
drugs [185,186], and UL97 itself is the target of maribavir
[187-189], a compound currently in phase III clinical tri-
als for treatment of HCMV-associated disease. The mutu-
ally exclusive and antagonistic actions of these drugs
[190] unfortunately prevent their simultaneous use in a
combination therapy regimen.
UL97 phosphorylates Rb and drives cell cycle progression,
functions which are carried out in uninfected cells by the
Cdks. In fact, UL97 can be described as a functional
ortholog of cellular Cdks because it rescues the cell cycle
defect in yeast cells lacking Cdk activity [163]. Interest-
ingly, UL97 appears to be an unregulated Cdk ortholog
that is not subject to the normal control mechanisms that
can be instituted to restrict cellular Cdk activity, such as
the requirement for activation by CAK-mediated phos-
phorylation and cyclin binding, and the inhibition by a
specific tyrosine phosphorylation or binding by the Ckis
[163].
Without the need for cyclin binding, we wondered how
UL97 was able to target Rb. Cellular cyclins have two
sequence elements that could direct Cdks to phosphor-
ylate Rb. The D-type cyclins have LxCxE motifs that bind
in the Rb pocket domain, and all cyclins have a hydropho-
bic patch that interacts with RxL motifs in C terminus of
the Rb protein. Interestingly, we found that UL97 con-
tains both motifs. In fact, UL97 has three LxCxE motifs,
although disruption of any individual site has minimal
effects on Rb phosphorylation [180]. We are currently
generating LxCxE and hydrophobic patch mutants to
determine if these sequences direct UL97 to phosphor-
ylate Rb.
Roles for viral IE proteins in modulating the Rb-E2F pathway
The HCMV Immediate Early-1 and -2 proteins (IE1 and
IE2) are promiscuous transcription factors. IE1 is required
for replication at low multiplicities of infection [191,192],
and stimulates cell cycle progression, but only in p53-nullCell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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or p21-null cells [193,194]. IE1, through its first 85 amino
acids, interacts with the Rb family member p107
[195,196], but not with Rb [197], and relieves p107-
mediated, but not Rb-mediated repression of an E2F-
responsive reporter [195]. A single report a decade ago
proposed that IE1 was a kinase that phosphorylated p107
and p130 (but not Rb) in vitro [198]. In vivo phosphoryla-
tion was not examined. That study identified a 23 amino
acid region within IE1 containing homology to the ATP-
binding sites of over 500 other kinases [198]. However,
our computer searches have not revealed this homology.
Furthermore, we have clearly shown that Rb is not phos-
phorylated in HCMV infected cells that express IE1 but do
not express UL97, indicating that IE1 likely does not play
a direct role in Rb phosphorylation during HCMV infec-
tion [163]. More experiments are needed to determine if
IE1 and/or UL97 is required for p107 and/or p130 phos-
phorylation in HCMV infected cells.
IE2 is absolutely required for lytic infection [199], and has
been reported to bind Rb both in vitro and in vivo [200-
202]. Amino acids 290–390 of IE2 are required for Rb
binding [201], and this binding is abrogated by cyclin A-
induced phosphorylation of Rb [200]. This binding could
contribute to Rb inactivation in combination with prior
pp71-mediated Rb degradation and subsequent UL97-
mediated Rb phosphorylation. Additionally, IE2 has been
shown to bind directly to the cyclin E promoter [203], and
IE2 mutants lacking the first 194 amino acids (but retain-
ing the putative Rb-binding region) fail to activate tran-
scription and are unable to stimulate the cell cycle [204].
Thus, IE2 modulation of the Rb-E2F pathway may actu-
ally bypass Rb and act directly on E2F-responsive promot-
ers.
The IE1 and IE2 transcripts share exons 1–3 and thus are
identical through their first 85 amino acids. Their subse-
quent sequences are different because of alternative splic-
ing of the gene, with IE1 using exon 4 and IE2 using exon
5. Interestingly, a viral mutant lacking exon 3 (IE1 and IE2
amino acids 30–77) is viable, but has a severe growth
defect, and importantly fails to fully activate the expres-
sion of cyclin E [205], an E2F-responsive gene. The defect
in cyclin E gene activation was not rescued by ectopic
expression of IE1, indicating that IE2 (and not IE1) is
required for full activation of cyclin E in HCMV infected
cells [205]. The expression of UL97 in cells infected with
this virus has not yet been examined and thus this mutant
virus may be defective in E2F-mediated gene expression
for multiple reasons. Interestingly, IE2 also arrests cell
cycle progression in early S phase by an unknown mecha-
nism [206,207].
Role of Rb inactivation during HCMV replication and pathogenesis
During HCMV infection, Rb is inactivated and E2F-
responsive genes are highly expressed [208]. Hypophos-
phorylated Rb is not found in HCMV-infected cells
because it is first degraded by pp71 and then phosphor-
ylated by UL97, and both of these phenomena should
induce the expression of E2F-responsive genes. Expression
of E2F-responsive genes also appears to be directly acti-
vated by IE2, independently of the Rb protein. Although
IE1 has been shown to stimulate the cell cycle when exog-
enously over expressed (in p53 or p21 mutant cells), it
does not appear to have a significant effect on cyclin E
expression in the context of an HCMV infection of wild-
type cells. It appears that HCMV encodes partially redun-
dant mechanisms to ensure efficient Rb inactivation and
robust E2F-responsive gene expression. The role of Rb
inactivation during HCMV replication and pathogenesis
is not yet known, but could be required for the accumula-
tion of nucleotide biosynthetic and other enzymes
involved in DNA replication that the virus could then
usurp for the replication of its own genome. The roles of
p107 and p130 during HCMV infection have not been
extensively studied, although a novel p130-containing
complex likely regulates cyclin E expression during HCMV
infection [209].
Human herpesvirus 6 and 7
We could find only one report of the effects of HHV-7 on
cell cycle progression. In that study [210], primary or
immortalized T cells infected at a low MOI (0.1 pfu/cell)
were observed to display elevated DNA contents after ten
days of infection similar to the 4n levels of DNA observed
in cells in the G2 or M phase of the cell cycle. While the
authors concluded that HHV-7 institutes a G2/M arrest, it
is unclear if the newly synthesized DNA observed in these
cells is viral or cellular. In fact, elevated levels of cyclin B
were observed in cells with DNA contents corresponding
to the G1, S, and G2/M phases of the cell cycle [210]. Lev-
els of Cdk1 were also increased following HHV-7 infec-
tion [210]. No other cell cycle markers were analyzed. The
results could be consistent with the authors' conclusion (a
G2/M arrest), or may mimic the results seen with HCMV,
where cells are arrested at the G1/S border but also express
cyclin B, and where the DNA content increase in infected
cells is attributed to viral, but not cellular DNA replication
[156,159].
More work has examined the effects of HHV-6 infection
on cell growth. T cells [211] or epithelial cells [212]
infected with HHV-6B, and glial precursor cells infected
with either HHV-6A or HHV-6B [213], stop dividing, rap-
idly cease synthesizing cellular DNA, and arrest with a G1/
S (2n) DNA content. The G1/S arrest was clearly shown in
glial precursor cells [213] by using a previously described
method [214,215] in which the microtubule depolymer-
izing agent nocodazole is used to trap cycling cells in the
G2/M phase, allowing for unambiguous quantitation of
cells trapped in G1. While the levels of the p53 tumor sup-
pressor are elevated in HHV-6 infected cellsCell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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[211,212,216] (as they are during HCMV infection), p21
levels are not elevated [212,217], and the G1/S arrest
appears to be p53-independent [212]. Cord blood mono-
nuclear cells infected with HHV-6A (and to a lesser extent
HHV-6B) showed significantly elevated levels of p53 and
cyclin B, and a modest induction of cyclins A and E [217].
Similar to the HHV-7 study [210], the conclusion of a G2/
M arrest based on the late accumulation of cells with a 4n
DNA content is complicated by the inability to distin-
guish viral and cellular DNA by flow cytometry.
No studies that analyzed the ability of HHV-6 or HHV-7
to stimulate cell cycle progression or to modulate the Rb-
E2F pathway at the molecular level could be found. There-
fore, we compared the amino acid sequences of the
HCMV proteins that modulate the Rb-E2F pathway
(pp71, IE2, and UL97) to their HHV-6 and HHV-7
orthologs (U54, U86, and U69, respectively) in an
attempt to predict how HHV-6 and HHV-7 may regulate
progression through the G1 phase of the cell cycle. The
pp71 orthologous U54 genes had no LxCxE motifs, indi-
cating that if it does modulate Rb, it does so in a manner
distinct from pp71. The IE2 orthologous U86 genes were
found to be around 20% identical and 65% similar to IE2
within the regions of IE2 implicated in cell cycle induction
(residues 1–194) and Rb binding (residues 290–390).
Because small functional motifs within these regions have
not been mapped, it is difficult to know whether this level
of homology can indicate that conserved or divergent
activities may be mediated by these protein domains. The
UL97 orthologous U69 genes lacked a discernable hydro-
phobic patch, and contained only a single LxCxE motif
that aligned with the first LxCxE motif in UL97. Interest-
ingly, these proteins robustly phosphorylate Rb in trans-
fected Saos-2 cells (Chad Kuny and Rob Kalejta,
manuscript in preparation). Thus it seems likely that
HHV-6 and -7 at least phosphorylate Rb through the
action of their virally encoded protein kinase. Whether or
not these viruses encode the multiple redundant func-
tions of HCMV that modulate this pathway remains to be
determined.
Betaherpesvirus summary
Although cellular Cdks don't appear to play a role in the
phosphorylation of Rb during HCMV infection, their
activity is required for efficient viral replication as evi-
denced by reduced viral yields in the presence of a Cdk
inhibitor such as roscovitine or a dominant-negative
Cdk2 [218-221]. Thus, analogous to the alphaherpesvi-
ruses, Cdks play a significant role in viral replication
despite their inability to phosphorylate Rb, and the rele-
vant cellular and viral targets of the Cdks in HCMV-
infected cells have yet to be identified. Although not a
result of Cdk activity, the Rb protein is efficiently inacti-
vated in HCMV infected cells, and E2F responsive genes
are highly expressed. The conspicuous absence of almost
all of the nucleotide biosynthetic enzymes encoded by the
alpha- and gammaherpesviruses (Fig. 2) indicates the pos-
sibility that the betaherpesviruses are hyper-dependent on
cellular enzymology for nucleotide synthesis and metabo-
lism (see below).
In terms of pathogenesis, numerous studies have found
HCMV, HHV-6, and HHV-7 genomes or proteins in can-
cerous cells or tissues [147,148,222]. However, the ubiq-
uitous nature of these viruses means that such association
studies need to be interpreted with caution. Certainly
HCMV encodes multiple proteins that stimulate the cell
cycle (Fig. 1) and that, theoretically, could have oncogenic
potential. Sequence analysis and preliminary data indi-
cate that at least one of the HHV-6 and HHV-7 orthologs
of those proteins, the UL97 orthologous U69 protein
kinases, are likely to have similar effects. In addition,
HCMV encodes numerous anti-apoptotic proteins [223]
and infection has been shown to prevent the death of
some cancerous cells [224]. If any of these pro-prolifera-
tive or anti-apoptotic proteins were to be driving forces
behind oncogenesis, their continued expression in tumors
would appear to be essential to maintain the transformed
phenotype. In addition, some HCMV proteins are muta-
genic [225] and thus may cause genomic instability lead-
ing to cancer through a "hit and run" mechanism. Thus,
multiple functions of these viruses could contribute to
oncogenesis.
However, infection with betaherpesviruses does not trans-
form cells in vitro. Furthermore, HCMV encodes many
proteins that can arrest cell cycle progression, such as
UL69 [226,227], IE2 [206,207] and UL117 (Yu, D. and
Qian, Z. 2008 International Herpesvirus Workshop
abstract). Furthermore, the HHV-6A U94 protein has been
reported to suppress H ras-mediated transformation
[228]. Many questions remain as to whether betaherpes-
virues are opportunistic bystanders or propelling forces
when they are found in human tumor samples, and if, in
analogy to the papillomaviruses, there are "high risk" and
"low risk" betaherpesviruses. The HCMV strains studied in
vitro were isolated from patients with various manifesta-
tions of disease (e.g. tonsilitis, retinitis, congenital infec-
tions, transplant patients), but none that we know of were
isolated from cancer patients. Comparisons of these
strains to ones isolated from patients with potentially
HCMV associated cancers may or may not reveal differ-
ences in the viral cell cycle regulatory proteins between
strains. Furthermore, because most of the proteins with
oncogenic potential are expressed only during lytic repli-
cation, it is unlikely that latently infected cells are trans-
formed (as is the case for the gammaherpesviruses; see
below), perhaps indicating that abortive or persistent
infections may be linked to oncogenesis. To complementCell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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the epidemiological studies, translational approaches
such as in vitro molecular analysis of betaherpesvirus
infected cells isolated from human tumors could begin to
answer the many confounding questions related to the
potential direct role of these viruses in human cancers.
Gammaherpesviruses
The human gammaherpesviruses [229-237] include
Epstein Barr Virus (EBV, HHV-4) and Kaposi's Sarcoma
Associated Herpesvirus (KSHV, HHV-8). EBV is common
within the population (over 90% are EBV positive),
infects B cells and epithelial cells, is transmitted orally,
and causes infectious mononucleosis [229]. EBV is also
associated with cancers, including B cell tumors such as
Burkit's lymphoma and Hodgkin's lymphoma, and epi-
thelial tumors such as nasopharyngial carcinoma
[229,230,238]. In these cancers, EBV is maintained in a
latent state. While most pathologies related to EBV are
caused by latent infection, lytic EBV is associated with the
proliferative disorder oral hairy leukoplakia in immuno-
compromised patients [229]. KSHV is uncommon in the
general population (less than 7%, but some geographical
areas have infection rates as high as 60%) infects B cells
and endothelial cells, and is transmitted sexually. A latent
KSHV infection is associated with Kaposi's Sarcoma, Pri-
mary Effusion Lymphoma (PEL), and a subset of Multi-
centric Castleman's Disease (MCD) [231,239]. The
gammaherpesviruses are characterized by their tropism
for lymphocytes, the association of their latent infections
with human cancers, and the difficulty in modeling their
lytic replication cycles in vitro [231].
Epstein Barr virus
Lymphoblastoid cell lines (LCLs) develop when primary
B-lymphocytes are infected in vitro with EBV [232,233].
LCLs are immortalized and transformed, so they prolifer-
ate and divide. Not surprisingly, they were found to have
higher levels of Cdks and G1 cyclins compared to primary
B-lymphocytes, and to harbor phosphorylated forms of
Rb and p107 [240,241]. EBV infection in LCLs is latent.
The viral genome is maintained as a circular episome and
is replicated mainly by cellular proteins, although EBNA-
1 (Epstein-Barr Nuclear Antigen – 1) is required for its rep-
lication and faithful partitioning during cell division
[232,233,242]. In LCLs, EBNA-1, EBNA-2, EBNA-3a,
EBNA-3c, EBNA-5 (EBNA-LP) and LMP1 (Latent Mem-
brane Protein – 1) cooperate to induce and maintain the
transformed phenotype [232,233]. A number of these
proteins (and a few others) have been reported to affect
the Rb-E2F pathway and are discussed below.
EBNA-5 does not have an LxCxE motif or hydrophobic
patch, but has been reported to bind Rb in GST pull down
experiments [243]. However, this protein was unable to
counteract the repressive effects of Rb or p107 on a
reporter construct under the control of a Gal4-E2F-1
fusion protein [244], so the relevance of Rb binding is
unknown. In cooperation with EBNA-2, EBNA-5 can acti-
vate the expression of cyclin D2 when overexpressed in
resting B cells stimulated with the viral gp350 envelope
protein [245]. The ability of other EBV latent proteins to
induce cyclin D2 expression under these conditions was
not analyzed. More direct assays are required to determine
if EBNA-5 can regulate the Rb-E2F pathway, and what role
such putative modulation may have in the creation of
LCLs upon EBV infection of primary B cells.
LMP-1 has also been reported to modestly induce cyclin
D2 expression, perhaps indicrectly through the induction
of the cMyc and AP1 transcription factors, and to main-
tain Rb in a hyperphosphorylated state in B cells treated
with TGF-β[246,247]. Other EBV latent proteins were not
analyzed for this function. Additional ways that LMP-1
may contribute to inducing E2F-mediated gene expres-
sion and cell cycle progression are by down regulating the
expression of the Cki p16 [248] through inducing the
nuclear export of the Ets2 transcription factor that induces
p16 expression [249], and by causing the nuclear export
of E2F-4 and -5 (the "inhibitor E2Fs") perhaps through
disrupting their ability to bind Rb [249]. Because D-type
cyclin expression is induced by growth factor signaling, it
is straightforward to imagine how a membrane protein
such as LMP-1 might activate cyclin D2 expression
through activation of the signaling cascade involved in
normal induction of cyclin D expression. It is more diffi-
cult to envision how such a protein may specifically regu-
late the nuclear export and complex formation of certain
transcription factors, unless this is an indirect effect.
The EBNA-3C protein has also been implicated in modu-
lating the Rb pathway. Although it lacks an LxCxE motif
or a discernable hydrophobic patch, early work reported
an interaction between in vitro translated and labeled
EBNA-3C and GST-Rb [250]. In this same study, EBNA-3C
also cooperated with activated ras to transform rodent
cells. This transformation was insensitive to inhibition by
over expression of p16 [250], leading the authors to spec-
ulate that inactivation of Rb, perhaps by inhibition of p16
or stimulation of cyclin D-dependent kinase activity was
the mechanism through which EBNA-3C contributed to
cellular transformation. A subsequent report showed that
EBNA-3C was required for the continued proliferation of
LCLs and for keeping the levels of both the p16 protein
and transcript low [251]. This compelling study proposed
that EBNA-3C may repress the transcription of p16, but
provided no mechanism, and no indication that repres-
sion of p16 was necessary or sufficient for EBNA-3C
induced proliferation of LCLs. A recent report proposed a
p16-independent way in which EBNA-3C may modulate
the Rb pathway. By translocating the mitochondrial pro-Cell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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tein MRS18-2 into the nucleus, EBNA-3C has been
reported to facilitate MRS18-2 binding to Rb and disrup-
tion of Rb-E2F complexes [252]. The mechanism by
which EBNA-3C could shuttle MRS18-2 to the nucleus
remains unexplored.
Other means through which EBNA-3C may modulate the
Rb pathway have also been proposed. EBNA-3C may
increase cyclin A-dependent kinase activity by associating
with cyclin A, disrupting its binding to the Cki p27, and
leading to p27 degradation [253,254]. While the C termi-
nus of EBNA-3C was required to render cyclin A insensi-
tive to p27 [253], the same group subsequently found an
N-terminal region of EBNA-3C (amino acids 130 to 159)
bound more strongly to cyclin A (and bound to cyclins D1
and E), and inhibited cyclin A-dependent kinase activity
[254]. Curiously, this same region (amino acids 140 to
149) was also implicated by this group in the EBNA-3C-
mediated degradation of p27 [255] and Rb, but not p107
or p130, by recruitment of the Skp2 ubiquitin ligase com-
plex [256]. It is unclear how this observation relates to the
ability of hypophosphorylated Rb in uninfected cells to
induce the degradation of Skp2 and thus result in cell
cycle arrest by preventing Skp2-mediated degradation of
p27 [257,258]. Because this small region of EBNA-3C may
have multiple and possibly important effects on cell cycle
progression, it is now critical to examine the role of this
region of EBNA-3C in the context of an EBV infection.
The EBV genes expressed in LCLs are referred to as the
latency III phenotype and can be expressed by EBV-posi-
tive cancers in immunocompromised patients [232,233].
Interestingly, in most natural latent EBV infections that
lead to cancers in immunocompotent hosts, fewer genes
are expressed. The only gene product implicated in Rb reg-
ulation that is consistently expressed in EBV positive
tumors is LMP-1 [232,233]. It is likely that the extra
latency III genes are initially expressed in vivo in all EBV
transformed cells. However, the growth advantage they
provide may be quickly outweighed by a propensity to
permit immune detection and clearance, and thus are
only consistently found in EBV transformed cells in vitro
or in immunocompromised hosts. Therefore, in immune
competent hosts, it is likely that an accumulation of addi-
tional cellular mutations (such as translocations that acti-
vate c-Myc expression) provide the growth or survival
advantages required for transformation in the absence of
latency III proteins. The required accumulation of these
mutations along with immune surveillance may explain
the low frequency with which natural infections lead to
cancer as compared to the much higher in vitro transfor-
mation efficiency of EBV.
When latent EBV is induced to reactivate a productive lytic
infection, the infected cells rapidly cease dividing and syn-
thesizing cellular DNA, and arrest at the G1/S border with
hyperphosphorylated Rb and elevated levels of cyclins E
and A [259,260]. The two viral proteins that drive lytic
reactivation, Z and R, may also play significant roles in
these cell cycle effects. When expressed alone, the EBV Z
protein has been shown to induce the expression of cer-
tain S phase genes, but also to arrest cell cycle progression
in both the G1 and G2 phases [261-263]. These effects
may be cell type specific. Thus Z appears to have similar
activities to the HCMV IE2 protein that induces and then
subsequently arrests cell cycle progression. The ability of
Z to directly bind to Rb has not been shown. The EBV R
protein does not have an LxCxE motif or a discernable
hydrophobic patch, but still binds to Rb [264] and stimu-
lates cell cycle progression [265]. In cells overexpressing R,
low levels of Rb, p107 and p130 were observed [265] but
the ability of R to degrade the Rb proteins was not exam-
ined. These cells also expressed high levels of E2F-1, and
eventually died by apoptosis. In addition to the cellular
E2F-responsive genes that likely contribute to viral DNA
replication during EBV lytic replication, the viral DNA
polymerase also appears to be an E2F-responsive gene
[266].
Small molecule Cdk inhibitors were able to inhibit EBV
lytic replication and viral gene expression [267]. In these
inhibitor treated cells, Rb was found to be hypophospho-
rylated, perhaps indicating that cellular Cdks are respon-
sible for phosphorylating Rb in lytically induced EBV
infected cells. However, we have shown that the HCMV
kinase UL97, and not the Cdks, phosphorylates Rb during
HCMV lytic replication. Furthermore, our preliminary
experiments indicate that the EBV ortholog of UL97, the
BGLF4 protein, can also phosphorylate Rb when trans-
fected into Saos-2 cells (Chad Kuny and Rob Kalejta, man-
uscript in preparation). Thus the small molecule Cdk
inhibitors may prevent the expression of BGLF4 during
EBV lytic reactivation, with BGLF4 (and not the Cdks)
being directly responsible for the phosphorylation of Rb.
More work is required to determine which kinase or
kinases phosphorylate Rb during lytic EBV infection, and
if the relevant targets of the small molecule Cdk inhibitors
that prevent EBV lytic infection are the "cell cycle" Cdks or
the "transcription" Cdks.
Kaposi's sarcoma associated herpesvirus
Latent KSHV infections are studied in vitro either in cell
lines established from PELs, or by infection of endothelial
cells to create ''spindle cells'', similar to those observed in
natural KS lesions. Cells latently infected with KSHV con-
sistently express three proteins; LANA (latency associated
nuclear antigen; ORF73), v-cyclin (viral cyclin; k-cyclin;
ORF72), and V-FLIP (viral FLICE inhibitory protein;
ORF71; K13) [268].Cell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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Although it lacks an LxCxE motif or a hydrophobic patch,
LANA binds to and inactivates Rb, and cooperates with H-
ras to transform rodent cells [269]. Proliferative diseases
were also observed in transgenic mice expressing LANA
from its endogenous promoter [270]. In addition to direct
inactivation, LANA has also been reported to inactivate Rb
through indirect mechanisms. By sequestering the GSK3β
kinase in the nucleus, LANA expression leads to the stabi-
lization of β-catenin, which in turn leads to the induction
of cyclin D1 expression and the subsequent stimulation of
G0 cells into the cell cycle [271]. LANA, and to a lesser
extent v-cyclin, increases the levels of Id-1, perhaps by a
post-transcriptional mechanism [272]. The Id proteins are
naturally occurring dominant negative inhibitors of basic
helix-loop-helix DNA binding transcription factors that
are implicated in many processes such as the inhibition of
differentiation and the stimulation of cell cycle progres-
sion [273]. However, because Id protein levels increase as
cells progress through the cell cycle, it is unclear if LANA
effects on Id-1 are direct or indirect, that is if they induce,
or are induced by, cell cycle progression. Regardless of the
mechanism(s), LANA expression has been clearly shown
to activate a subset of E2F-responsive genes [274] presum-
ably through Rb inactivation, because reporter assays and
in vitro binding studies indicate that LANA is likely unable
to inactivate either p107 or p130.
KSHV also encodes an ortholog of cellular cyclin D (v-cyc-
lin) that is expressed during both lytic replication and
latency [268,275-280] and phosphorylates Rb [276,281-
283]. v-cyclin lacks the LxCxE motifs found in the D-type
cyclins, but does have a hydrophobic patch that is highly
conserved among herpesvirus-encoded cyclins [284]. It is
not known whether the hydrophobic patch is required for
Rb phosphorylation. Although it can bind to Cdk2, 4, 5,
and 9, v-cyclin preferentially pairs with Cdk6
[276,281,282]. v-cyclin/Cdk6 complexes have an
extended substrate range (compared to cyclin D/Cdk6)
that includes targets of cyclin E and cyclin A
[276,277,281,285-289]. In addition, v-cyclin is immune
to a number of cellular control mechanisms that can
attenuate the activity of cellular cyclin/Cdk complexes
[290]. For example, v-cyclin lacks a destruction box so it is
more stable than cellular cyclins [291], it is immune from
inhibition by the Ckis [285,286,292], accumulates in the
nucleus [293], and supports Cdk6 kinase activity in the
absence of CAK phosphorylation [293,294]. Outside the
context of a KSHV infection, v-cyclin can cooperate to
transform rodent cells in culture and promote lymphoma
formation in transgenic mice [295]. Through the phos-
phorylation and stabilization of p53 v-cyclin causes a G1
cell cycle arrest [296], so cell cycle stimulation and trans-
formation is more readily observed in p53 mutant cells.
Cells from latent KSHV infections or associated cancers,
however, are not growth inhibited, potentially through
the modulation of the p53 pathway by LANA [297]. Our
preliminary evidence indicates that the KSHV-encoded
kinase, the ORF36 protein, can also lead to Rb phosphor-
ylation (Chad Kuny and Rob Kalejta, manuscript in prep-
aration), indicating another potential mechanism for Rb
inactivation during lytic replication.
Induction of lytic infection in PEL cell lines with TPA pre-
vents them from entering the S phase [298] inducing an
accumulation of cells with a G1 DNA content [299]. At
least two lytic phase viral proteins seem to be involved in
this G1 arrest. The K-bZIP protein (also known as RAP
(replication associated protein) or K8), the structural and
positional ortholog of the EBV Z protein, arrests cells in
G1 [298,299]. Potential mechanisms for this arrest are the
activation of p53 by direct binding [300], the stimulation
of the transcription of the gene for the Cki p21 [298], and/
or by directly binding and inhibiting cyclin E/A/Cdk2
complexes [299]. Interestingly, while K-bZip seems to
share cell cycle functions with EBV Z, it is unable to induce
lytic reactivation of latent KSHV infections [301]. This
function seems to be confined to KSHV Rta, the ortholog
of the EBV R protein [302,303]. The other lytic phase pro-
tein that has been shown to arrest PEL cells in G1, the viral
G protein coupled receptor (v-GPCR, ORF74), likely does
so through a p21-dependent mechanism [304]. This is
intriguing in light of the fact that vGPCR is considered a
transforming oncogene [305-309].
The viral cyclin is expressed during lytic infection as well
[276,277]. Interestingly, the MGHV-68 cyclin is required
for reactivation from latency [310]. Whether this is true or
not for KSHV remains to be examined, but v-cyclin has
been shown to phosphorylate different residues of p27 in
latently and lyticaly infected cells [287], indicating that it
may have important roles during both latency and lytic
reactivation.
Gammaherpesvirus summary
In contrast with the alpha- and betaherpesviruses there is
a clear association of gammaherpesviruses with prolifera-
tive disorders including a number of cancers. Further-
more, both EBV and KSHV appear to encode proteins that
modulate the Rb-E2F pathway, either directly or indirectly
(Fig. 1). However, what appears to be an unambiguous
case of cause and effect may not be so straightforward.
EBV certainly encodes transforming proteins required for
the maintenance of LCLs created in vitro. However, most
of those are not expressed in the majority of naturally aris-
ing EBV positive tumors. So while these proteins can
transform cells, and EBV does cause cancer, the Rb-inacti-
vating viral proteins that may help initiate transformation
are not always required for the maintenance of the trans-
formed state. Such a view fits well with the ability of EBV
to potentially activate cellular E2F-responsive genes byCell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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inactivating Rb (Fig. 1) while encoding a full complement
of viral nucleotide biosynthetic enzymes (Fig. 2).
Similarly, while KSHV encodes Rb inactivating proteins
(Fig. 1), a provocative study found that the Rb pathway
could be reconstituted in KSHV infected PEL cells by
expressing the Cki p16 [311]. The six PEL cell lines and
four PEL tumor samples tested in this study were all found
to be deficient for p16. Furthermore, when PEL cells were
transduced with a recombinant adenovirus expressing
p16, they arrested in the G1 phase of the cell cycle, and
this arrest required the presence of the Rb protein [311].
Thus, even though PEL cells express LANA and v-cyclin,
additional mutations (such as loss of p16) appear to be
required to fully inactivate the Rb pathway. So even for
the gammaherpesviruses, viral infection may not be suffi-
cient for the complete inactivation of the Rb pathway that
is required for carcinogenesis.
Interestingly, although Rb inactivating proteins such as v-
cyclin are also expressed during lytic KSHV infection, this
is unlikely to result in an increase in cellular E2F gene
product accumulation. The KSHV-encoded SOX (shut-off
and exonuclease; ORF37) protein mediates a broad shut-
off of host gene expression [312-314] by causing the rapid
turnover of more than 75% of host transcripts, while only
2% of host transcript levels increase in response to KSHV
infection [315]. KSHV is likely immune to potetially neg-
ative effects of the downregulation of E2F responsive
genes because it encodes the most nucleotide biosynthetic
enzymes of any herpesvirus (Fig. 2).
Nucleotide biosynthetic enzymes (NBEs) and human 
herpesvirus infections
What effects do the many different ways that the human
herpesviruses regulate the Rb protein (to inactivate it or
keep it active) have in the context of viral infection? Rb
controls the E2F transcription factors, and many E2F-
responsive genes are involved in DNA replication, a proc-
ess required by all human herpesviruses to replicate their
own genomes. But all the human herpesviruses seem to
encode most of the enzymology required for the actual
process of DNA synthesis (Fig. 2). So if cellular helicases,
primases, and polymerases aren't needed for viral genome
replication, than what cellular factors, if any, are?
We hypothesize that the nucleotide biosynthetic enzymes
(NBEs) represent the key Rb-E2F-regulated gene products
of interest to the human herpesviruses. However, not all
human herpesviruses appear to have an equal interest in
these genes. As alluded to earlier, the alpha- and gamaher-
pesviruses encode between five and seven enzymes
involved in nucleotide metabolism, whereas the betaher-
pesviruses encode only one activate enzyme (Fig. 2). Not
surprisingly, by mining published [315-317] and unpub-
lished (Szpara and Enquist, personal communication)
microarray studies, we found that a select set of cellular
NBEs is elevated in HCMV infected cells, but not in HSV-
1 or KSHV-infected cells (Fig. 3).
We selected a set of eleven cellular NBEs to analyze based
on two criteria. First, we picked six cellular enzymes (TK1,
RRM2, DUT, UNG, DHFR, TYMS) that have a virally
encoded counterpart in at least one human herpesvirus.
The second criteria was that the NBE was present on the
arrays used to analyze changes in the expression patterns
of cellular genes after infection with at least two of the
three viruses (HSV-1, HCMV, and KSHV) for which we
could access the primary data. There were five genes in this
category (AK1, NME7, PPAT, CTPS, PFAS). We analyzed
the available microarray data to determine if the expres-
sion level of these genes changed after viral infection.
For KSHV, we found that during lytic infection, none (0/
11) of the cellular NBEs analyzed were upregulated (Fig.
3). In fact, many were downregulated, likely due to the
action of the viral SOX protein. KSHV can likely succeed
without the need of cellular NBEs because it encodes the
most viral NBEs of any human herpesvirus (Fig. 2). We
could not find a microarray analysis of latently infected
KSHV cells, but we would expect to see upregulated
expression of the cellular NBEs because the viral NBEs are
not expressed during latency. We could not access the data
for the only EBV study we found in the literature[318].
We found a similar absence of upregulated cellular NBEs
during lytic (1/11) infections of HSV-1 (Fig. 3). These
results aren't surprising because HSV-1 encodes many
viral NBEs that are expressed during lytic infection and
encodes a nuclease (VHS) that can degrade cellular
mRNAs. We did not analyze an HSV-1 latency microarray
study. However, HSV-1 establishes latency in non-divid-
ing neurons and thus doesn't need to replicate its genome
to high levels and we suspect cellular NBE levels to be low
in latently infected neurons. We could not find a microar-
ray analysis of HSV-2 or VZV infected cells.
In contrast, HCMV infection upregulated more (4/11) of
the cellular NBEs during lytic infection (Fig. 3). Both the
promoter and enzymatic activity of one enzyme not
upregulated in the microarray study, DHFR, was found to
be increased in HCMV infected cells [319,320], and thus
we could set the activated fraction even higher (5/11). Fur-
thermore, the virus may not need the activity of two of the
other enzymes because the UL97 protein that phosphor-
ylates the nucleoside analog ganciclovir[185,186] may be
able to phosphorylate other nucleosides, and thus may
functionally replace TK1 and NME7. HCMV likely relies
on cellular NBEs because it encodes only one catalytically
active viral NBE (Fig. 2). This was surprising as HCMV hasCell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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the largest genome and the most genes of the human her-
pesviruses. We could not find microarray analysis of latent
HCMV, HHV-6, or HHV-7 infections. What is not readily
apparent is why or how the alpha- and gammaherpesvi-
ruses evolved to encode most of their own NBEs, while the
betaherpesviruses seem to rely heavily on cellular
enzymes. An intriguing hypothesis is that, by evolving
multiple mechanisms to inactivate Rb, HCMV and per-
haps betaherpesviruses in general may have eliminated
their need to encode their own NBEs. The fact that beta-
herpesviruses each encode two catalytically inactive NBEs
seems to lend credence to this theory. It would be interest-
ing to determine if the expression of a full cadre of virus
NBEs would obviate the need for some of the Rb inactivat-
ing proteins encoded by HCMV.
Conclusion
In addition to inducing the expression of cellular NBEs,
there appear to be two other reasons why herpesviruses
may modulate the Rb-E2F pathway. First, by manipulat-
ing this pathway, they can synchronize infected cells in a
cell cycle position that favors the efficient replication of
their DNA genomes, and by extension, their productive
lytic replication cycles. Such synchronization appears to
require both cell cycle stimulatory and arrest functions.
This favorable cell cycle position can be thought of as the
G1 phase for all the herpesvirus classes. G1 arrest presum-
ably is beneficial because preventing the replication of the
cellular genome allows for the unencumbered utilization
of DNA precursors and replication enzymes for the sole
production of viral genomes. While this hypothesis for
the presumed benefit that cell cycle arrest seen during her-
pesvirus lytic infections provided for these viruses is com-
monly invoked (and makes perfect sense), there is
surprisingly little direct evidence to support it. It is known
that replication of HCMV, the largest and slowest human
herpesvirus, is delayed and decreased by an IE2 point
mutant that fails to arrest cell cycle progression [321].
However it is unclear if the inability to arrest the cell cycle
is the only deficiency shown by this mutant allele of this
essential HCMV protein. Furthermore, as herpesviruses
such as HSV-1 and EBV have smaller genomes and repli-
cate much faster, it might be expected that competition for
nucleotides would have a quantitatively smaller effect on
these viruses. More work is needed to determine why G1
appears to be a favored cell cycle position for herpesvirus
lytic replication.
The second reason why herpesviruses may modulate the
Rb-E2F pathway is to facilitate cell division and thus the
expansion of the reservoir of latently infected cells. While
lytic replication can rapidly increase the number of
infected cells within a host, and the progeny virions that
are created can mediate transmission to new hosts, lyti-
cally-infected cells are short-lived and subject to intrinsic,
innate, and adaptive immune defenses. Latency permits
the long term persistence of infected cells that may be less
visible to the immune system. If latently infected cells pro-
liferate, or could be induced to proliferate, the reservoir of
such cells could be expanded.
Thus, both lytic and latent infections of herpesviruses
could conceivably benefit from modulation of the host
cell cycle in general and the Rb-E2F pathway in particular.
Below we summarize the data presented above for a rep-
resentative member of each class of human herpesviruses
(please see the companion figure, Fig. 4).
HSV-1, an alphaherpesvirus
Lytic replication
Cell cycle arrest functions are expressed (ICP0, ICP27),
but no cell cycle stimulatory functions are expressed. Cells
arrest in early G1 phase. The expression of many virally-
encoded nucleotide biosynthetic enzymes (Fig. 2) likely
renders HSV-1 relatively insensitive to changes in E2F-
mediated gene expression.
Latency
Cell cycle effects in latently infected cells are unknown,
but because latency is established in terminally differenti-
ated sensory neurons and few viral genes are expressed,
any effects would be expected to be minimum. The non-
dividing nature of the latent reservoir appears to render
HSV-1-independent of E2F-mediated gene expression
during latency. Sensory neurons would seem to be a non-
renewable resource, so reactivations would either need to
be non-cytolytic, or very judiciously initiated. The expres-
sion of viral nucleotide biosynthetic enzymes during reac-
tivation may allow for lytic replication without cell cycle
induction, perhaps improving the chances for the survival
of the latently infected neuron after lytic reactivation.
HCMV, a betaherpesvirus
Lytic replication
Cell cycle arrest (UL69, IE2, UL117) and stimulatory
(pp71, IE1, IE2, UL97) functions are expressed. Infected
cells are arrested at the G1/S border. The absence of many
nucleotide biosynthetic enzymes encoded within the
HCMV genome (Fig. 2) appears to make this virus
dependent upon cellular E2F-responsive genes for effi-
cient lytic replication.
Latency
Cell cycle effects during latent HCMV infections have not
been examined. However, because few if any genes are
expressed, and because transformation or immortaliza-
tion of latently infected cells has not been demonstrated,
it is unlikely that latency modulates the cell cycle. The
absence of many HCMV-encoded nucleotide biosynthetic
enzymes implies that reactivation requires cellular E2F-Cell Division 2009, 4:1 http://www.celldiv.com/content/4/1/1
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mediated gene expression. Whether this leads to death of
the reactivated cell is unclear. Because the undifferentiated
cells that likely harbor latent virus would appear to be a
renewable resource, the eventual death of the reactivating
cell may have few consequences for the formation of life-
long latency except for the need for continual reseeding of
the latent reservoir.
EBV, a gammaherpesvirus
Lytic replication
Cell cycle arrest (Z) and stimulatory (R) functions are
expressed. Infected cells arrest in late G1 phase. The
expression of many EBV-encoded nucleotide biosynthetic
enzymes (Fig. 2) likely renders EBV relatively insensitive
to changes in E2F-mediated gene expression.
Latency
Cell cycle stimulatory functions are expressed in type I
(LMP-1) and type III (LMP-1, EBNA-3C, EBNA-LP)
latency, but cell cycle arrest functions are not. Latently-
infected primary B cells are immortalized and trans-
formed. They proliferate and divide, and so the virus must
replicate and partition its genome to maintain the latent
reservoir. The lack of expression of virally-encoded nucle-
otide biosynthetic enzymes during latency appears to
make EBV reliant upon E2F-mediated cellular gene
expression for viral DNA replication. Note that during
latency, the amount of viral DNA replication (which is
mediated by host cell polymerases) is negligible com-
pared to the amount of host cell DNA being synthesized
(in contrast to what happens during lytic infection).
Because the B cells that harbor latent virus represent a
renewable resource, the eventual death of the reactivating
cell may have little effect on the ability of EBV to establish
lifelong latency. Because latently infected cells can expand
in number, a continual reseeding of the latent reservoir
may not be necessary.
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